Progenity
Biora Therapeutics Settles Claims of Misleading Genetic Testing Advertisements
The company, formerly known as Progenity, was accused of violating consumer protection laws by making misleading claims about the costs of its genetic testing services.
Biora Therapeutics Divests Preeclampsia Test to Avero Diagnostics
Biora previously operated as a women's health diagnostic company called Progenity, but in mid-2021 shifted its focus to drug delivery and therapeutics.
The firm alleges its competitors infringe its patents describing processes for finding chromosomal abnormalities in fetal cell-free DNA.
Enumera Molecular Acquires Progenity Liquid Biopsy Tech, Raises $12.5M in Series A Round
Progenity will receive an ownership stake in the newly formed venture, which is being headed by its former CSO Matthew Cooper.
Progenity, Natera Jointly Request Dismissal of Patent Litigation
Progenity sought a declaratory judgment from a California court last year that its Innatal NIPT test didn't infringe six patents held by Natera.
Jun 15, 2021
Progenity Raises $40M in Private Placement
May 13, 2021
Progenity Q1 Revenues up 46 Percent
Feb 23, 2021
Progenity Enters $25M Private Placement
Nov 9, 2020
Progenity Q3 Revenues Increase 38 Percent
Oct 23, 2020